Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of early deferasirox in transfusion-dependent myelodysplastic syndromes with early iron loading
ISRCTN62162141Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jan 2013
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in myelodysplastic syndrome (MDS) and transfusional hemosiderosis, sponsored by University of Birmingham. Primary endpoint: Time to reach a ferritin of 1500 ug/L. Started Jan 2013; status: completed.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)transfusional hemosiderosis
Beyond the preview
Go deeper on ISRCTN62162141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN62162141.